Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and another hormone, appears to offer a significant advancement for body management . Early patient trials have shown https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide